Quick answers
- What is Neomycin sulfate, polymyxin b sulfate and bacitracin zinc used for?
- The FDA-approved label (Neomycin and Polymyxin B Sulfates and Bacitracin Zinc, Bausch & Lomb Incorporated, January 2, 2025) says: “Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Neomycin sulfate, polymyxin b sulfate and bacitracin zinc have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Neomycin sulfate, polymyxin b sulfate and bacitracin zinc?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Neomycin sulfate, polymyxin b sulfate and bacitracin zinc been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Neomycin sulfate, polymyxin b sulfate and bacitracin zinc?
- 1 company lists prescription products of Neomycin sulfate, polymyxin b sulfate and bacitracin zinc in the FDA NDC Directory, including Bausch & Lomb Incorporated.
What Neomycin sulfate, polymyxin b sulfate and bacitracin zinc is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.
— FDA label: Neomycin and Polymyxin B Sulfates and Bacitracin Zinc, Bausch & Lomb Incorporated, effective January 2, 2025. Read the full label on DailyMed →
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Forms and how it is given
| Dosage forms | Ointment |
|---|---|
| Route | Ophthalmic |
| Prescription products | 1 in the FDA NDC Directory |
| Brand names | Neomycin and Polymyxin B Sulfates and Bacitracin Zinc |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| bacitracin zinc 400 USP units/g · neomycin sulfate 0.35% · polymyxin b sulfate 10000 USP units/g ointment | Generic | $4.57 per gram |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bausch & Lomb Incorporated1 product
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (1)
- ANDA064064Bausch and Lomb Inc · October 30, 1995
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 308493 |
|---|---|
| SPL set ID of the quoted label | f3231f1c-665e-4efa-baa1-83bf296b2f8f |
| FDA labels (SPL) | 1 |
| FDA applications | 1 ANDA |
| Active ingredients (FDA) | BACITRACIN ZINC / NEOMYCIN SULFATE / POLYMYXIN B SULFATE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Neomycin and Polymyxin B Sulfates and Bacitracin Zinc, Bausch & Lomb Incorporated, effective January 2, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →